Cargando…

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy

Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are com...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yixin, Zhang, Zheyang, Li, Tianhao, Li, Xin, Zhang, Sainan, Li, Ying, Zhao, Wenyuan, Gu, Yunyan, Guo, Zheng, Qi, Lishuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813654/
https://www.ncbi.nlm.nih.gov/pubmed/31681618
http://dx.doi.org/10.3389/fonc.2019.01094
_version_ 1783462884200677376
author Liu, Yixin
Zhang, Zheyang
Li, Tianhao
Li, Xin
Zhang, Sainan
Li, Ying
Zhao, Wenyuan
Gu, Yunyan
Guo, Zheng
Qi, Lishuang
author_facet Liu, Yixin
Zhang, Zheyang
Li, Tianhao
Li, Xin
Zhang, Sainan
Li, Ying
Zhao, Wenyuan
Gu, Yunyan
Guo, Zheng
Qi, Lishuang
author_sort Liu, Yixin
collection PubMed
description Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are commonly based on risk scores summarized from gene expression, are unsuitable for clinical application because of their high sensitivity to experimental batch effects and quality uncertainties of clinical samples. Using 226 samples of HGS-OvCa patients receiving platinum-taxane ACT in TCGA, we developed a qualitative transcriptional signature, consisting of four gene pairs whose within-samples relative expression orderings could robustly predict patient recurrence-free survival (RFS). In two independent test datasets, the predicted non-responders had significantly shorter RFS than the predicted responders (log-rank p < 0.05). In a test dataset containing data for patient pathological response state, the signature reclassified 12 out of 22 pathological complete response patients as non-responders and two out of 16 pathological non-complete response patients as responders. Notably, the 12 predicted non-responders in the pathological complete response group had significantly shorter RFS than the predicted responders (log-rank p = 0.0122). This qualitative transcriptional signature, which is insensitive to experimental batch effects and quality uncertainties of clinical samples, can individually identify HGS-OvCa patients who are more likely to benefit from platinum-taxane adjuvant chemotherapy.
format Online
Article
Text
id pubmed-6813654
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-68136542019-11-01 A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy Liu, Yixin Zhang, Zheyang Li, Tianhao Li, Xin Zhang, Sainan Li, Ying Zhao, Wenyuan Gu, Yunyan Guo, Zheng Qi, Lishuang Front Oncol Oncology Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are commonly based on risk scores summarized from gene expression, are unsuitable for clinical application because of their high sensitivity to experimental batch effects and quality uncertainties of clinical samples. Using 226 samples of HGS-OvCa patients receiving platinum-taxane ACT in TCGA, we developed a qualitative transcriptional signature, consisting of four gene pairs whose within-samples relative expression orderings could robustly predict patient recurrence-free survival (RFS). In two independent test datasets, the predicted non-responders had significantly shorter RFS than the predicted responders (log-rank p < 0.05). In a test dataset containing data for patient pathological response state, the signature reclassified 12 out of 22 pathological complete response patients as non-responders and two out of 16 pathological non-complete response patients as responders. Notably, the 12 predicted non-responders in the pathological complete response group had significantly shorter RFS than the predicted responders (log-rank p = 0.0122). This qualitative transcriptional signature, which is insensitive to experimental batch effects and quality uncertainties of clinical samples, can individually identify HGS-OvCa patients who are more likely to benefit from platinum-taxane adjuvant chemotherapy. Frontiers Media S.A. 2019-10-18 /pmc/articles/PMC6813654/ /pubmed/31681618 http://dx.doi.org/10.3389/fonc.2019.01094 Text en Copyright © 2019 Liu, Zhang, Li, Li, Zhang, Li, Zhao, Gu, Guo and Qi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Yixin
Zhang, Zheyang
Li, Tianhao
Li, Xin
Zhang, Sainan
Li, Ying
Zhao, Wenyuan
Gu, Yunyan
Guo, Zheng
Qi, Lishuang
A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
title A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
title_full A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
title_fullStr A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
title_full_unstemmed A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
title_short A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy
title_sort qualitative transcriptional signature for predicting recurrence risk for high-grade serous ovarian cancer patients treated with platinum-taxane adjuvant chemotherapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813654/
https://www.ncbi.nlm.nih.gov/pubmed/31681618
http://dx.doi.org/10.3389/fonc.2019.01094
work_keys_str_mv AT liuyixin aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT zhangzheyang aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT litianhao aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT lixin aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT zhangsainan aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT liying aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT zhaowenyuan aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT guyunyan aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT guozheng aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT qilishuang aqualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT liuyixin qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT zhangzheyang qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT litianhao qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT lixin qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT zhangsainan qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT liying qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT zhaowenyuan qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT guyunyan qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT guozheng qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy
AT qilishuang qualitativetranscriptionalsignatureforpredictingrecurrenceriskforhighgradeserousovariancancerpatientstreatedwithplatinumtaxaneadjuvantchemotherapy